Good morning :)
$
₹
Nuvectis Pharma Inc

Nuvectis Pharma Inc

NVCT

NASDAQ
Asset Logo

Nuvectis Pharma Inc

NVCT

NASDAQ
$22.610.71% (-0.16)
$
₹
$22.610.71% (-0.16)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $783.1M the stock is ranked 2997

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

87.79
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.32
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 6 analysts' reports

Buy
6 analysts
Hold
0 analyst
Sell
0 analyst

Analysts expect a +57.40% price upside over the next year

Current Price$22.61
Target Price$35.4

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
70.27
70.27
1Y Return
19.4%
19.4%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
24.43
24.43
1Y Return
41.48%
41.48%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
27.25%
27.25%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.83
30.83
1Y Return
32.43%
32.43%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.06
20.06
1Y Return
42.89%
42.89%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Nuvectis Pharma Inc -87.79-
AbbVie Inc70.2750.450.36
Amgen Inc24.4320.222.10

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

-7.4
-7.3
-6
-7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue00026.79000000
Net Income-4.17-4.42-4.15-6.24-5.33-6.33-7.46-7.31-6.05-7.02
Net Profit Margin----23.31%------
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Nuvectis Pharma Inc (NVCT) share price today is $22.61 as of September 11, 2026 at 1:30 AM IST. The stock touched a day high of $22.90 and a day low of $22.03.

  2. Nuvectis Pharma Inc stock trades on NASDAQ under the ticker symbol NVCT.

  3. Nuvectis Pharma Inc's market capitalization is $783.13M as of September 11, 2026 at 1:30 AM IST.

  4. Nuvectis Pharma Inc's price-to-earnings (P/E) ratio is N/A as of September 10, 2026.

  5. Nuvectis Pharma Inc's price-to-book (P/B) ratio is 87.79 as of September 10, 2026.

  6. Yes, You can buy Nuvectis Pharma Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Nuvectis Pharma Inc shares in three steps: 1. Search Nuvectis Pharma Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Nuvectis Pharma Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Nuvectis Pharma Inc (NVCT) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.4421 shares at the current price of $22.61.

Loading...